'Exceptional' grant to help boost our regional networks and help us reach more people across the UK.
Kat, a Macmillan Haematology Nurse Specialist, shares how attending our Lymphoma Masterclass helped her focus for the year ahead.
Brentuximab vedotin recommended as treatment option for systemic anaplastic large cell lymphoma.
Some people with CLL now able to access venetoclax through Cancer Drugs Fund.
People with certain mutations (genetic changes) in their lymphoma cells are most likely to benefit.
MOR2018 and lenalidomide could be a new treatment combination for diffuse large B-cell lymphoma (DLBCL) that has relapsed (come back) or was refractory (didn’t respond well) to previous treatment.
New approaches are needed for the treatment of people with T-cell lymphoma after disappointing results in the CHEMO-T trial.
Adding rituximab to chemotherapy improves outcomes for under-18s with advanced-stage B-cell non-Hodgkin lymphoma (NHL)
Recently published findings from the phase 3 RATHL trial (Response-adapted therapy for advanced Hodgkin lymphoma) show that most people can be spared some side effects.